Harrow, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- Harrow, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $64.52M.
- Harrow, Inc. stock issued during period, value, new issues for fiscal 2023 was $64.52M.
- Harrow, Inc. stock issued during period, value, new issues for fiscal 2017 was $2.94M, a 73.48% decline from fiscal 2016.
- Harrow, Inc. stock issued during period, value, new issues for fiscal 2016 was $11.09M.
- Harrow, Inc. stock issued during period, value, new issues for fiscal 2009 was $50.36K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $64.52M 10-K · filed 2026-03-02 |
| 2023-09-30 | $64.52M 10-Q · filed 2024-11-14 | |
| 2017-12-31 | $2.94M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $11.09M 10-K · filed 2018-03-08 | |
| 2009-12-31 | $50.36K 10-K · filed 2014-03-28 | |
| 2007-12-31 | $25.50K 10-K · filed 2013-03-18 | |
| 2006-12-31 | $2.40K 10-K · filed 2013-03-18 | |
| 2005-12-31 | $15.70K 10-K · filed 2013-03-18 | |
| 2000-12-31 | $6.00K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |